Susquehanna International Group
PSTX

Susquehanna International Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Susquehanna International Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-198,375
Closed -$1.9M – 13802
2024
Q4 		$1.9M Buy
+198,375
New +$1.04M ﹤0.01% 5427
2024
Q3 		– Sell
-16,006
Closed -$49.5K – 13287
2024
Q2 		$46.7K Sell
16,006
-17,837
-53% -$48.8K ﹤0.01% 11437
2024
Q1 		$108K Sell
33,843
-21,081
-38% -$70.3K ﹤0.01% 11171
2023
Q4 		$185K Buy
54,924
+28,834
+111% +$74.3K ﹤0.01% 10761
2023
Q3 		$62.1K Sell
26,090
-15,280
-37% -$32K ﹤0.01% 11198
2023
Q2 		$72.8K Sell
41,370
-610,024
-94% -$1.56M ﹤0.01% 11153
2023
Q1 		$2.01M Buy
651,394
+403,618
+163% +$2.42M ﹤0.01% 5136
2022
Q4 		$1.31M Buy
247,776
+83,675
+51% +$383K ﹤0.01% 5585
2022
Q3 		$579K Buy
+164,101
New +$543K ﹤0.01% 8093
2022
Q1 		– Sell
-16,863
Closed -$115K – 14174
2021
Q4 		$115K Buy
+16,863
New +$115K ﹤0.01% 12041
2021
Q2 		– Sell
-48,451
Closed -$434K – 13406
2021
Q1 		$463K Buy
+48,451
New +$475K ﹤0.01% 9661

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's PSTX Position: Q1 2025 in Review

Susquehanna International Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 198,375 shares — an estimated $1.9M sold.

Susquehanna International Group first reported a position in PSTX in Q1 2021 and held it in 11 quarters. The position peaked at $2.01M in Q1 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Susquehanna International Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 198,375 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.9M.
  • Susquehanna International Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Susquehanna International Group's Poseida Therapeutics, Inc. Common Stock position peaked at $2.01M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.